載入中
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
前收盤價
US$6.97
−US$0.13 · -1.83%
盤中時間採用ET。市場資料可能有所延遲。
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
日內區間
目前US$6.97
52週區間
目前US$6.97
盤中時間採用ET。市場資料可能有所延遲。
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
日內區間
目前US$6.97
52週區間
目前US$6.97
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 8198.3萬 USD | 8004.6萬 USD | 8321.5萬 USD | 7125.5萬 USD | 6111.5萬 USD |
| 銷售、一般及管理費用 | 2124.5萬 USD | 1800.6萬 USD | 1600.8萬 USD | 1526.3萬 USD | 1330萬 USD |
| 營業費用 | 1.03億 USD | 9805.2萬 USD | 9922.3萬 USD | 1.19億 USD | 9166.5萬 USD |
| 利息收入 | 104萬 USD | 339萬 USD | 307.5萬 USD | 104.1萬 USD | 6.6萬 USD |
| 利息支出 | — | — | — | 104.1萬 USD | — |
| 折舊和攤銷 | 16.8萬 USD | 13.4萬 USD | 11.1萬 USD | 7.7萬 USD | 8.5萬 USD |
| 營業利益 | −1.03億 USD | −9805.2萬 USD | −9922.3萬 USD | −1.19億 USD | −9166.5萬 USD |
| 淨利 | −9717.2萬 USD | −1.01億 USD | −9361.2萬 USD | −1.2億 USD | −9294.5萬 USD |
公司資料更新於 2026年10月17日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$28.67
上漲空間 311.33%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI371.15萬0.00%2.3兆 USD0.03%US$374.07-1.15%
Vanguard Extended Market ETFVXF148.1萬0.00%912億 USD0.05%US$226.57-1.80%
iShares Micro-Cap ETFIWC30.65萬0.02%12.8億 USD0.60%US$173.28-2.53%
Simplify Propel Opportunities ETFSURI21.42萬0.30%7239.93萬 USD2.82%US$17.06620.00%
Avantis U.S. Small Cap Equity ETFAVSC12.44萬—30.74億 USD0.25%US$69.30-0.86%
ALPS Medical Breakthroughs ETFSBIO11.72萬0.07%1.73億 USD0.50%US$50.12-4.02%
Invesco NASDAQ Future Gen 200 ETFQQQS5.36萬0.25%2125.18萬 USD0.20%US$38.3927-4.16%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCSimplify Propel Opportunities ETFSURIAvantis U.S. Small Cap Equity ETFAVSCALPS Medical Breakthroughs ETFSBIOInvesco NASDAQ Future Gen 200 ETFQQQSAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
